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Summary
Background: Increase in lipid levels associated with the treatment of inflammatory 
bowel disease (IBD) has previously been reported. However, it is unknown if this ef-
fect is similar for all IBD drug classes.
Aim: To precisely assess the effect of different IBD drug classes on lipid profiles
Methods: We performed a systematic literature search of randomised controlled tri-
als and observational cohort studies that assessed lipid levels before and after induc-
tion (≤10 weeks) and maintenance (>10 weeks) of IBD treatment. Data of 11 studies 
(1663 patients) were pooled using random effects models. The influence of patient 
and disease characteristics on treatment effects on total cholesterol levels was ana-
lysed in 6 studies (1211 patients) for which individual data were available, using linear 
mixed models.
Results: A statistically significant increase in total cholesterol was observed after in-
duction treatment with corticosteroids (+1.19 mmol/L, 95% confidence interval [CI95] 
+0.52 to +2.59), and tofacitinib (+0.66 mmol/L, CI95 +0.42 to +0.79), but not after 
anti- TNFα treatment (− 0.11 mmol/L, CI95 − 0.26 to +0.36 mmol/L). Similar differences 
were observed after maintenance treatment. Treatment effects were significantly 
related to age, but not with other factors. Lipid changes were inversely correlated 
with but not modified by CRP changes.
Conclusions: Increase in total cholesterol levels was strongest for corticosteroids 
followed by tofacitinib but was not observed for anti- TNFα agents. Whether total 
cholesterol change associated with IBD treatment has an effect on cardiovascular 
risk requires further study.
2  |     SLEUTJES ET aL.
1  | INTRODUC TION
Over the last 50 years, cardiovascular disease mortality has de-
clined drastically due to improved primary and secondary pre-
vention. However, this trend is decelerating as the prevalence 
of obesity and type 2 diabetes increase, and even early signs 
of reversal are shown in some populations.1 Therefore, long- 
term prognosis implies that cardiovascular disease will remain 
one of the most important causes of morbidity and mortality 
worldwide.
In analogy to other chronic inflammatory diseases, such as rheu-
matoid arthritis and psoriasis, inflammatory bowel disease (IBD) is 
associated with an increased risk of cardiovascular disease.2,3 This 
elevated risk cannot be explained by traditional risk factors only, as 
the prevalence of obesity, hypertension and dyslipidaemia are similar 
or even lower in IBD patients compared to the general population.4,5 
Indeed, chronic systemic inflammation is considered an independent 
cardiovascular risk factor.
Counterintuitively, patients with an active chronic inflamma-
tory disease have lower levels of total cholesterol, high- density 
lipoprotein cholesterol (HDL- c) and low- density lipoprotein cho-
lesterol (LDL- c) compared to patients who are in disease remission 
and the general population.6 This so- called “lipid paradox” has been 
mirrored in other inflammatory states, amongst others rheumatoid 
arthritis and sepsis.7 However although absolute lipid levels are 
lower, the properties of the lipid particles tend to be more pro- 
atherogenic, with a shift towards relatively more small dense LDL- c 
and pro- inflammatory and pro- thrombotic characteristics of HDL- c 
associated with a higher risk of thrombus formation.8,9 The severity 
of the underlying inflammation is associated with the magnitude of 
these lipid changes.
Randomised controlled trials and observational studies in 
patients with IBD, comprising Crohn's disease (CD) and ulcer-
ative colitis (UC), demonstrated increases in lipid levels after 
therapy initiation. Recently, awareness of these changes was 
provoked by the results of the tofacitinib registration trials. 
After 8- week induction therapy, a significant increase of total 
cholesterol, HDL- c and LDL- c levels was observed, which stabi-
lised during maintenance therapy.10 An inverse association was 
observed between the increase of lipid levels and C- reactive 
protein (CRP) levels.11 In addition to janus kinase inhibitors, lipid 
changes have been described in relation with other IBD thera-
pies, such as corticosteroids and anti- tumour necrosis factor- 
alpha (TNFα) agents.12- 14
The translation of the study findings to clinical practice is chal-
lenging. For example, it is unknown if lipid levels are affected simi-
larly by all classes of IBD therapy. Systematic analyses of available 
data might provide some guidance. Against this background, we 
performed a systematic review and meta- analysis of randomised 
trials and observational studies of IBD treatment, with the main 




This systematic review was performed according to the Cochrane 
Handbook for Systematic Reviews of Interventions15 and re-
ported according to the Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses (PRISMA) guidelines.16 We followed 
an a priori established protocol which is published at PROSPERO 
(CRD42019123338). In October 2018, a literature search was 
performed in electronic databases Embase, Medline Ovid, Web of 
Science, Cochrane CENTRAL and Google Scholar to identify pub-
lished and unpublished literature. The electronic literature search 
(Table S1) was conducted by an expert librarian (WB); the final run 
was performed in December 2020. No time or language restrictions 
were applied. Abstracts from major gastroenterology conferences 
(Digestive Disease Week, European Crohn's and Colitis Organization, 
United European Gastroenterology Week, the American College of 
Gastroenterology, Digestive Disease Week and Crohn's and Colitis 
Foundation) were searched manually (2000- 2020). Reference lists 
were read to identify additional studies. Institutional review board 
approval was not required. De- identified data were provided with 
data transfer agreements.
2.2 | Study selection
Two reviewers (JS and RP) independently scanned titles and abstracts 
to determine eligibility. Articles were selected if they met inclusion 
criteria: (a) randomised controlled trials (RCT) or observational cohort 
studies, (b) population consisted of IBD patients, including ulcera-
tive colitis (UC) and Crohn's disease (CD), (c) intervention with IBD 
drug therapy, including 5- aminosalicylic acids, steroids, immunosup-
pressants, biologicals, Janus Kinase/Signal Transducer and Activator 
of Transcription (JAK- STAT) inhibitors and calcineurin inhibitors, (d) 
serum levels of total cholesterol, HDL- c, LDL- c and/or triglycerides 
were measured before and after initiation of aforementioned therapy, 
(e) minimum sample size of 20 participants. Exclusion criteria were (a) 
case reports, in vitro and animal studies, and (b) studies that solely 
investigated the effect of dietary supplements, probiotics, parenteral 
nutrition, or gastrointestinal surgery. There were no restrictions re-
garding intensity, frequency or timing of the intervention.
2.3 | Data extraction and quality assessment
Data extraction and quality assessment were performed in du-
plicate by the two authors individually. Collected data consisted 
of: (a) first author's name, (b) year of publication, (c) study design, 
(d) type of intervention, (e) number of participants in treatment 
groups, (f) treatment duration, (g) concomitant medication use at 
baseline, (h) age, (i) sex, (j) IBD diagnosis, (k) disease duration, (l) 
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disease extent, (m) body mass index (BMI) and (n) serum levels of 
total cholesterol, HDL- c, LDL- c, triglycerides and CRP at baseline 
and during follow- up. Authors were approached by email if they 
were willing to share individual datasets, or alternatively, complete 
data request forms with instructions for analysis prior to data 
transfer. Assessment of quality was performed using Cochrane 
Collaboration Tool for RCTs and Newcastle Ottawa Scale for ob-
servational cohort studies.17,18
2.4 | Outcome
The primary outcome was serum total cholesterol change after induc-
tion and maintenance treatment. Secondary outcomes were changes 
in HDL- c, LDL- c and triglycerides. Assuming that the plateau phase 
observed after tofacitinib induction therapy applies to other drug 
classes, lipid changes from baseline were analysed after induction 
(≤10 weeks) and maintenance treatment (first visit after >10 weeks).19
2.5 | Data synthesis and analysis
All our meta- analyses are performed on log2 transformed lipid data 
to obtain normal distributions. If necessary, mg/dL were converted 
to mmol/L using 38.67 as convergence factor for total cholesterol, 
HDL- c and LDL- c, and 88.5 for triglycerides, respectively. For each 
drug class, study- specific mean changes (follow- up minus baseline) 
in lipid levels were pooled using random- effect models, while apply-
ing the method of Fleming and DeMets (1996).20 Effect sizes were 
expressed as pooled mean difference (MD) on the Log2 scale, along 
with 95% confidence intervals (CI95), and visualised by forest plots. 
For ease of understanding, effect sizes are also presented on the lin-
ear scale (in mmol/L), using the pooled mean baseline value as refer-
ence. The degree of heterogeneity between studies was analysed by 
I2 statistics and expressed in percentage of variation (>50% substan-
tial).21 Risk of publication bias was explored using visual inspection 
of funnel plot asymmetry and objectively judged using the Egger's 
regression test, provided that sufficient studies were eligible in line 
with recommendations.22
When available, mean differences between baseline and fol-
low- up values, standard deviations (SD) and standard errors (SE) 
were directly determined using individual patient data (calculated 
ourselves or obtained from investigators). Mean differences based 
on aggregated data were calculated as the difference between the 
reported mean baseline and follow- up values. The SD of the mean 
difference was then estimated as
with r being the Pearson correlation coefficient between the baseline 
and follow- up measurement, which was estimated using the available 
individual patient data of the drug class concerned.
To analyse possible (modifying) effects of patient and disease 
characteristics on drug- induced total cholesterol changes, individ-
ual patient data were analysed using linear mixed- effect models, 
assuming a random intercept between studies, as well as between 
subjects within studies, and a fixed slope for predictor variables.23 
We considered age, sex, BMI, CRP, IBD subtype, disease duration 
and steroid use at baseline as potential influencing factors (Table S2).
A two- sided P- value <0.05 was considered statistically signifi-
cant for all statistical tests. Data analyses were performed in SAS® 
9.4 Software (M7 2020).
3  | RESULTS
3.1 | Eligible studies
The study selection process is shown in Figure 1. The systematic 
search identified 2561 citations. After title and abstract evaluation, 
2504 were excluded not meeting inclusion criteria. Of the 57 arti-
cles selected for full- text search and review, 31 were excluded be-
cause of various reasons. One review article yielded one extra study, 
resulting in the inclusion of 27 articles for qualitative synthesis. 
Agreement between reviewers for trial eligibility was good (κ sta-
tistic 0.74). We successfully contacted 11 authors: from 8 studies 
individual patient data were shared,9,10,13,14,24- 27 from three studies 
aggregated data were provided.28- 30
3.2 | Description of studies
Characteristics of included studies are summarised in Table 1. 
Included studies were published between 2012 and 2020. 
Of the 11 included studies, eight were observational cohort 
studies9,13,14,24,25,27- 29 and three RCT (two phase 2 and one phase 
3).10,26,30 Percentage of IBD patients (n = 1663) diagnosed with CD 
and UC were 15% (n = 250) and 85% (n = 1413), respectively. All 
studies provided data on sex and age; nine studies on BMI and dis-
ease duration; and seven on concomitant steroid use. All individual 
patient datasets contained information on CRP levels at baseline and 
during follow- up. The intervention period ranged between 8 weeks9 
and 3 years.14 None of the studies stated hyperlipidaemia or the use 
of lipid- lowering drugs as exclusion criteria.
3.2.1 | Treatment regimens
Three studies investigated lipid effects of corticosteroids (n = 73), 
four of anti- TNFα agents (n = 207), five of tofacitinib (n = 1257), 
one of filgotinib (n = 128) and one of cyclosporine (n = 72). The 
treatment regimen of corticosteroids consisted of (a) methylpred-
nisolone weekly dose intravenous bolus- administered vs conven-








− 2 ⋅ r ⋅ SDbaseline ⋅ SDfollow - up,
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F I G U R E  1   Flow diagram of study selection procedure for systematic review and meta- analysis
3,843 articles identified in 
search Embase, Medline Ovid, 
Web of Science, Cochrane 
CENTRAL and Google Scholar
2,504 excluded based on title and abstract
57 included for full text 
search and review
31excluded after reading full text
1 study in pre-clinical phase
1 sample size insufficient
1 hyperlipidemic non-IBD population 
1 no provision of cholesterol results
5 duplication of data
12 lacking adequate before/after lipid profiles 
10 review articles
3 reviews used for reference
3 without focus on cholesterol outcomes
4 IBD not taken into account
27 articles included for 
qualitative synthesis
2,561 remaining after 
removal of duplicates
1 article extracted from reference list
11 studies included for 
systematic review 
and meta-analysis
16 excluded after data extraction
3 no continuous data available 
1 no baseline values available
1 access to dataexpired
3 data requestsdeclined






















11 studies included in random effect models
8 studies included in linear mixed models
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starting from 450 mg/wk) and (b) next- generation budesonide- 
MMX orally (8- week regimen of 9 mg stable dose). In the third 
study, the specification of type and dose of corticosteroids was 
not disclosed.9,27,29 Anti- TNFα agents used included infliximab 
only,9,28 either infliximab or adalimumab (n = 104 and n = 10, re-
spectively),14 and unspecified anti- TNFα agents.29 Two studies 
reported concomitant use of steroids at baseline.28,29 No data on 
dosing or interval of anti- TNFα agents were available.14 Three to-
facitinib studies included were randomised clinical trials10,26 and 
two were real- life cohorts.24,25 In these studies different treat-
ment induction doses were used (range 0.5- 15 mg), but mainte-
nance regimens were similar in all studies (5 mg or 10 mg twice 
daily).10,24- 26 In the tofacitinib cohorts, concomitant steroid use at 
baseline varied from 36.3% to 50%.
3.2.2 | Lipid levels before and after therapy
Eight studies reported lipid changes after induction and five stud-
ies after maintenance treatment. Data on modification of lipid levels 
were available for total cholesterol (11 studies), HDL- c (8 studies), 
LDL- c (8 studies) and triglycerides (7 studies).
3.3 | Quality and risk of bias
Details of the quality assessment are shown in Tables S3 and S4. 
Two observational cohort studies featured a control group, namely 
healthy controls13 and other chronic inflammatory conditions.9 Two 
studies were of high quality (≥7 stars allocated)9,13 and six studies 
of moderate quality, either due to no selection of a non- exposed 
cohort,14,24,25,27- 29 insufficient length of follow- up (<4 weeks)29 and/
or incomplete assessment of lipid levels during follow- up (<80%).25,29 
The randomised controlled trials had a low risk of bias.10,26,30 Test for 
publication bias by funnel plot was not performed since less than 
10 studies per outcome were included in the meta- analysis, thus 
the power of the test was too low to distinguish change from real 
asymmetry.
3.4 | Results of meta- analysis
3.4.1 | Lipid changes in different IBD drug classes
Results of meta- analyses on drug- induced lipid changes are shown in 
Figures 2- 5 and Table 2.
For corticosteroids, significant changes in total cholesterol lev-
els were observed after induction (mean change 1.19 mmol/L, CI 
0.52 and 2.59, P = 0.007) and maintenance therapy up to 14 weeks 
(mean change 1.33 mmol/L, CI95 0.28 and 2.26, P = 0.003) with high 
rates of heterogeneity (I2 86% and 83%, respectively). No significant 
changes in triglyceride levels were observed after short- term treat-
ment. None of the studies assessed HDL- c or LDL- c changes.
Use of anti- TNFα agents was not associated with total choles-
terol changes after induction therapy and maintenance therapy 
(mean change −0.11 mmol/L, CI −0.26 and 0.36, P = 0.455 and mean 
change 0.08 mmol/L, CI −0.07 and 0.39, P = 0.466, respectively), 
nor long- term changes in HDL- c, LDL- c or triglyceride levels were 
observed. Only one study assessed short- term changes in HDL- c, 
LDL- c and triglycerides [30143407]. Levels of heterogeneity were 
low in all analyses.
After induction treatment with tofacitinib, total cholesterol was 
increased (mean change 0.66 mmol/L, CI 0.42 and 0.79, P < 0.001), 
as was HDL- c (mean change 0.25 mmol/L, CI 0.10 and 0.30, 
P < 0.001) and LDL- c (mean change 0.35 mmol/L, CI 0.20 and 0.47, 
P < 0.001). Similar changes were observed after maintenance treat-
ment (mean change 0.55 mmol/L, CI 0.43 and 0.68, P < 0.001; mean 
change 0.18 mmol/L, CI 0.14 and 0.21, P < 0.001; mean change 
0.42 mmol/L, CI 0.28 and 0.62, P < 0.001). Triglyceride levels de-
creased after induction and maintenance treatment which reached 
statistical significance only after maintenance treatment (mean 
change −0.06 mmol/L, CI −0.10 and −0.01, P = 0.012). High rates of 
heterogeneity were present between studies evaluating the short- 
term effect of tofacitinib on lipid profiles (I2 90%- 95%).
In filgotinib, increases in total cholesterol, HDL- c, LDL- c and tri-
glycerides were observed after induction treatment (mean change 
+0.39 mmol/L [SD ±0.87], P < 0.001; mean change +0.24 mmol/L 
[SD ±0.40], P < 0.001; mean change +0.15 mmol/L [SD ±0.68], 
P = 0.199; and mean change +0.007 mmol/L [SD ±0.59], P = 0.877, re-
spectively) and maintenance treatment (mean change +0.28 mmol/L 
[SD ±0.85], P = 0.003; mean change +0.05 mmol/L [SD ±0.45], 
P = 0.085; mean change +0.16 mmol/L [SD ±0.63], P = 0.024; and 
mean change +0.16 mmol/L [SD ±1.10], P = 0.313, respectively).
Only one study assessed the effect of cyclosporine on lipid lev-
els. No short term data were available. After a median treatment 
duration of 9.4 months with cyclosporine, a significant difference 
in total cholesterol and triglycerides were reported (mean change 
+1.62 mmol/L [SD ±1.38]; and mean change +0.73 mmol/L [SD 
±1.73], respectively).
3.4.2 | Effect of patient and disease characteristics 
on drug- induced lipid changes
Data of 1211 patients from 6 studies9,10,13,24,26,27 were available for 
analyses of the influence of sex, age, BMI, CRP, IBD subtype, dis-
ease duration, disease extent and concomitant corticosteroid use 
at baseline on drug- induced changes in total cholesterol. Neither 
of these factors had a meaningful influence on the mean change in 
total cholesterol between baseline and 10 weeks follow- up (Table 3; 
compare Models 1 and 2). Reliable estimates of any treatment modi-
fying effect could be obtained in 1135 patients using tofacitinib. The 
degree of the tofacitinib- induced increase in total cholesterol was 
significantly related to age, but not with the other factors (Table 3; 
Models 3). An increase was seen even in the youngest patients 
(18 years: +0.39 mmol/L). A reverse relationship with CRP changes 
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was observed for total cholesterol, HDL- c and LDL- c but not triglyc-
eride changes, both in the total population (R −0.204, R −0.182, R 
−0.101, P < 0.001 and R 0.016, P = 0.293, respectively) as for all 
individual treatments.
4  | DISCUSSION
In this meta- analysis of aggregated and individual patient data, we 
demonstrated significant and persistent lipid changes in IBD patients 
starting corticosteroids and tofacitinib independent of treatment 
regimens. In addition, tofacitinib increased HDL- c and LDL- c and re-
duced triglyceride levels significantly both after induction and main-
tenance therapy. The effect of anti- TNFα agents on total cholesterol 
changes was neutral. Lipid data of other agents used in IBD were 
limited or unavailable. Elevation of total cholesterol levels was modi-
fied by age and inversely correlated with CRP levels.
As expected, patients treated with corticosteroids showed the 
most prominent increase in total cholesterol levels after induction 
treatment up to 14 weeks. Baseline total cholesterol levels were signifi-
cantly lower in the corticosteroids group, which might reflect the se-
verity of underlying disease since corticosteroids are mostly indicated 
TA B L E  1   Baseline characteristics of included studies in systematic review and meta- analysis
Drug





































Corticosteroids Farkas (2014)9 OS 19 12 13 (68.4) 36.4 (±14.8) 23.2 (±4.7) CD 6 (31.6)
UC 13 (6.8)





9.4 (5.9- 15.1) 3.88 (±1.10) MD MD 1.20 (±0.74) 4, 8, 12
Pigniczki (2019)13 OS 22 8 6 (27.3) 43.1 (±15.2) 27.1 (±4.4) UC 22 (100) 7.9 (±6.5) NA E1: 5 (22.7)
E2: 10 (45.5)
E3: 7 (31.8)
7.4 (2.5- 12.3) 4.82 (±0.70) MD MD 1.27 (±0.55) 8
Motobayashi (2018)27 OS 31 52 12 (39) 40 (±15) NA UC 31 (100) 6 (±5.5) NA MD 2.6 (0.9- 6.7) 3.75 (±0.75) MD MD MD 2, 13, 52
Anti- TNFα 
agents
Schulte (2018)29 OS 35 26 19 (54.3) 37.2 (±14.8) 24.9 (±4.1) CD 22 (62.9)
UC 13 (37.1)
4.5 (±6.5) NA MD 4.6 (1.7- 9.8) 4.75 (±0.81) 1.38 (±0.49) 2.69 (±0.61) 1.52 (±0.69) 6, 26
Miranda- Bautista 
(2014)14
OS 128 156 64 (50) 43.6 (±12.8) 23.9 (±4.6) CD 92 (71.9)
UC 36 (28.1)





1.4 (0.8- 2.5) 4.68 (±1.10) 1.37 (±0.45) 2.62 (±1.84) 3.28 (±1.92) 52, 156
Balint (2013)28 OS 25 26 11 (45.8) 39.2 (±11.9) MD UC 25 (100) 9.2 (±7.8) 25 (100) MD MD 5.17 (±1.41) MD MD 1.36 (±0.67) 42
Motobayashi (2018)29 OS 21 52 9 (43) 45 (±16) NA UC 21 (100) 8 (±5.3) NA MD 2.6 (0.9- 6.7) 3.59 (±1.22) MD MD MD 2, 13, 52
Tofacitinib Honap (2020)24 OS 93 8 56 (60) 41.7 (±16.8) MD UC 93 (100) 9.1 (±9.0) 38 (41) MD 4 (2- 13.3) 4.49 (±1.20) 1.58 (±0.60) 2.48 (±0.89) MD 8
Biemans (2019)25 OS 45 12 27 (58.7) 43.3 (±14.3) 25.0 (±3.80) UC 45 (100) 12.2 (±10.4) 21 (45.7) E1: 9 (21.4)
E2: 10 (23.8)
E3: 23 (54.8)
5.2 (2.0- 12.9) 4.65 (±1.03) 1.42 (±0.48) 2.80 (±0.85) 1.52 (±0.75) 12
OCTAVE phase 2 
(2012)26
RCT 146 8 83 (56.8) 41.3 (±14.1) 25.5 (±4.4) 146 (100) 9.3 (±7.7) 53 (36.3) E1: 47 (32.2)
E2: 41 (28.1)
E3: 51 (34.9)
6.1 (2.0- 16.5) 4.92 (±1.00) 1.42 (±0.43) 2.90 (±0.76) 1.30 (±0.68) 8
OCTAVE phase 3 
Induction 1 (2017)10
RCT 467 8 277 (58.2) 41.1 (±13.5) 24.7 (±5.0) 467 (100) 8.3 (±7.1) 214 (45.0) E1: 67 (15.7)
E2: 149 (34.8)
E3: 108: (49.3)
4.7 (1.9- 12.0) 4.73 (±0.96) 1.51 (±0.48) 2.66 (±0.74) 1.22 (±0.59) 8
OCTAVE phase 3 
Induction 2 (2017)10
RCT 429 8 259 (60.4) 41.0 (±13.5) 25.1 (±5.0) 429 (100) 7.9 (±6.9) 198 (46.2) E1: 69 (16.1)
E2: 151 (35.2)
E3: 214 (49.9)
5.0 (2.1- 11.8) 4.65 (±1.01) 1.47 (±0.45) 2.61 (±0.80) 1.27 (±0.61) 8
Filgotinib FITZROY phase 2 
(2016)30
RCT 130 20 59 (45) 37.4 (±11.6) 23.8 (±4.3) CD 130 (100) 8.8 (±8.5) 65 (50) L1: 24 (18)
L2: 29 (22)
L3: 77 (59)
8.2 (3.1- 17.0) 4.57 (±0.94) 1.46 (±0.49) 2.46 (±0.80) 1.43 (±0.70) 10, 20
Cyclosporine Balint (2013)28 OS 72 26 33 (45.8) 40.3 (±13.7) 23.6 (5.1) UC 72 (100) 13.5 (±9.8) 72 (100) MD MD 4.45 (±1.23) MD MD 1.44 (±0.66) 42
Note: Categorical variables are described as number (%); continuous variables are expressed in mean (SD), except CRP and lipid parameters described  
in median (IQR).
Abbreviations: BMI, body mass index; CD, Crohn's disease; CRP, C- reactive protein; HDL- c, high density lipoprotein cholesterol; LDL- c, low density  
lipoprotein cholesterol; MD, missing data; MMX, Multi Matrix®; n, number of patients; OS, observational study; RCT, randomised controlled trials;  
UC, ulcerative colitis.
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in acute episodes to induce disease remission. Moreover, 30%- 50% of 
patients in the anti- TNFα and tofacitinib group used concomitant corti-
costeroids at baseline. Clinical trials of tofacitinib in rheumatoid arthri-
tis, psoriasis and psoriatic arthritis patients showed similar lipid changes 
in the first 3 months of treatment.31- 33 Interestingly, in these conditions 
anti- TNFα agents were associated with a relative increase in total cho-
lesterol, HDL- c and triglyceride levels as well.34,35 Therefore effect on 
lipids of immune- modulating drugs might be partly disease- specific.
In agreement with other studies, we found a reverse relationship 
between CRP levels and total cholesterol, HDL- c and LDL- c, that 
supports the hypothesis that suppression of inflammation partially 
explains lipid increases. However, the variable degree and pattern 
of the observed lipid changes between drug classes suggests a drug- 
specific mechanism of action as well. Corticosteroids influence lipid 
metabolism via hormonal, enzymatic and receptor pathways. Lipids 
increase directly or secondarily to corticosteroid- induced metabolic 
effects including down- regulation of LDL- c receptors, insulin re-
sistance and inhibition of lipolysis.36 Lipid increasing effects were 
even present in the topically- acting budesonide with low systemic 
availability.27,37 The relationship between the janus kinase path-
way and lipid metabolism is unclear. A mechanism of action study 
in RA patients demonstrated that tofacitinib- induced lipid increases 
TA B L E  1   Baseline characteristics of included studies in systematic review and meta- analysis
Drug





































Corticosteroids Farkas (2014)9 OS 19 12 13 (68.4) 36.4 (±14.8) 23.2 (±4.7) CD 6 (31.6)
UC 13 (6.8)





9.4 (5.9- 15.1) 3.88 (±1.10) MD MD 1.20 (±0.74) 4, 8, 12
Pigniczki (2019)13 OS 22 8 6 (27.3) 43.1 (±15.2) 27.1 (±4.4) UC 22 (100) 7.9 (±6.5) NA E1: 5 (22.7)
E2: 10 (45.5)
E3: 7 (31.8)
7.4 (2.5- 12.3) 4.82 (±0.70) MD MD 1.27 (±0.55) 8
Motobayashi (2018)27 OS 31 52 12 (39) 40 (±15) NA UC 31 (100) 6 (±5.5) NA MD 2.6 (0.9- 6.7) 3.75 (±0.75) MD MD MD 2, 13, 52
Anti- TNFα 
agents
Schulte (2018)29 OS 35 26 19 (54.3) 37.2 (±14.8) 24.9 (±4.1) CD 22 (62.9)
UC 13 (37.1)
4.5 (±6.5) NA MD 4.6 (1.7- 9.8) 4.75 (±0.81) 1.38 (±0.49) 2.69 (±0.61) 1.52 (±0.69) 6, 26
Miranda- Bautista 
(2014)14
OS 128 156 64 (50) 43.6 (±12.8) 23.9 (±4.6) CD 92 (71.9)
UC 36 (28.1)





1.4 (0.8- 2.5) 4.68 (±1.10) 1.37 (±0.45) 2.62 (±1.84) 3.28 (±1.92) 52, 156
Balint (2013)28 OS 25 26 11 (45.8) 39.2 (±11.9) MD UC 25 (100) 9.2 (±7.8) 25 (100) MD MD 5.17 (±1.41) MD MD 1.36 (±0.67) 42
Motobayashi (2018)29 OS 21 52 9 (43) 45 (±16) NA UC 21 (100) 8 (±5.3) NA MD 2.6 (0.9- 6.7) 3.59 (±1.22) MD MD MD 2, 13, 52
Tofacitinib Honap (2020)24 OS 93 8 56 (60) 41.7 (±16.8) MD UC 93 (100) 9.1 (±9.0) 38 (41) MD 4 (2- 13.3) 4.49 (±1.20) 1.58 (±0.60) 2.48 (±0.89) MD 8
Biemans (2019)25 OS 45 12 27 (58.7) 43.3 (±14.3) 25.0 (±3.80) UC 45 (100) 12.2 (±10.4) 21 (45.7) E1: 9 (21.4)
E2: 10 (23.8)
E3: 23 (54.8)
5.2 (2.0- 12.9) 4.65 (±1.03) 1.42 (±0.48) 2.80 (±0.85) 1.52 (±0.75) 12
OCTAVE phase 2 
(2012)26
RCT 146 8 83 (56.8) 41.3 (±14.1) 25.5 (±4.4) 146 (100) 9.3 (±7.7) 53 (36.3) E1: 47 (32.2)
E2: 41 (28.1)
E3: 51 (34.9)
6.1 (2.0- 16.5) 4.92 (±1.00) 1.42 (±0.43) 2.90 (±0.76) 1.30 (±0.68) 8
OCTAVE phase 3 
Induction 1 (2017)10
RCT 467 8 277 (58.2) 41.1 (±13.5) 24.7 (±5.0) 467 (100) 8.3 (±7.1) 214 (45.0) E1: 67 (15.7)
E2: 149 (34.8)
E3: 108: (49.3)
4.7 (1.9- 12.0) 4.73 (±0.96) 1.51 (±0.48) 2.66 (±0.74) 1.22 (±0.59) 8
OCTAVE phase 3 
Induction 2 (2017)10
RCT 429 8 259 (60.4) 41.0 (±13.5) 25.1 (±5.0) 429 (100) 7.9 (±6.9) 198 (46.2) E1: 69 (16.1)
E2: 151 (35.2)
E3: 214 (49.9)
5.0 (2.1- 11.8) 4.65 (±1.01) 1.47 (±0.45) 2.61 (±0.80) 1.27 (±0.61) 8
Filgotinib FITZROY phase 2 
(2016)30
RCT 130 20 59 (45) 37.4 (±11.6) 23.8 (±4.3) CD 130 (100) 8.8 (±8.5) 65 (50) L1: 24 (18)
L2: 29 (22)
L3: 77 (59)
8.2 (3.1- 17.0) 4.57 (±0.94) 1.46 (±0.49) 2.46 (±0.80) 1.43 (±0.70) 10, 20
Cyclosporine Balint (2013)28 OS 72 26 33 (45.8) 40.3 (±13.7) 23.6 (5.1) UC 72 (100) 13.5 (±9.8) 72 (100) MD MD 4.45 (±1.23) MD MD 1.44 (±0.66) 42
Note: Categorical variables are described as number (%); continuous variables are expressed in mean (SD), except CRP and lipid parameters described  
in median (IQR).
Abbreviations: BMI, body mass index; CD, Crohn's disease; CRP, C- reactive protein; HDL- c, high density lipoprotein cholesterol; LDL- c, low density  
lipoprotein cholesterol; MD, missing data; MMX, Multi Matrix®; n, number of patients; OS, observational study; RCT, randomised controlled trials;  
UC, ulcerative colitis.
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are driven by decreased cholesterol ester catabolism and improved 
anti- atherogenic HDL- c function.38 To our knowledge, evidence on 
the pathomechanisms of TNFα inhibition on the lipid metabolism is 
limited. TNFα is suggested to promote hepatic lipogenesis, induce 
lipolysis and regulate cholesterol metabolism and other adipocyte- 
derived adipokines.39 In IBD, anti- TNFα agents did not influence 
small dense LDL- c levels despite significant improvement of disease 
activity.9 Moreover, anti- TNFα administration is associated with 
beneficial cardiovascular effects such as improvement of insulin 
sensitivity, endothelial function and coronary plaque stability.40,41
Our study showed that women have more unfavourable lipid 
profiles as compared to men. Sex differences in lipid profiles of IBD 
F I G U R E  2   Mean change in total cholesterol after induction and maintenance therapy
-0,5 -0,4 -0,3 -0,2 -0,1 0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1
Total cholesterol, MD
Log2
-0,5 -0,4 -0,3 -0,2 -0,1 0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1
Total cholesterol, MD
Log2
Induction Study MD 95% LL 95% UL P-value I2
Corticosteroids Farkas (2014) [9] 0.59 0.38 0.79
Motobayashi (2018) [28] 0.40 0.25 0.54
Pigniczki (2019) [13] 0.17 0.07 0.26
Pooled 0.37 0.16 0.75 0.007 86%
Anti-TNFα Schulte (2018) [30] -0.05 -0.12 0.03
Motobayashi (2019) [28] 0.19 0.12 0.27
Pooled -0.04 -0.14 0.06 0.455 4%
Tofacitinib Honap (2020) [25] 0.19 0.13 0.25
OCTAVE phase 2 (2012) [27] 0.12 0.09 0.16
OCTAVE P3 I1 (2017) [10] 0.20 0.18 0.23
OCTAVE P3  I2 (2017) [10] 0.24 0.22 0.26
Pooled 0.19 0.14 0.24 <0.001 91%
Maintenance Study MD 95% LL 95% UL P-value I2
Corticosteroids Farkas (2014) [9] 0.40 0.25 0.54
Motobayashi (2018) [28] 0.60 0.45 0.75
Pooled 0.45 0.16 0.75 0.003 83%
Anti-TNFα Schulte (2018) [30] -0.01 -0.10 0.08
Miranda-Bautista (2014) [28] 0.01 -0.05 0.08
Balint (2013) [29] 0.00 -0.27 0.27
Motobayashi (2018) [28] 0.23 0.19 0.27
Pooled 0.07 -0.09 0.22 0.466 26%
Tofacitinib Biemans (2019) [26] 0.21 0.19 0.23
OCTAVE Sustain (2017) [10] 0.16 0.14 0.18
Pooled 0.16 0.13 0.20 <0.001 16%
F I G U R E  3   Mean change in HDL- c after induction and maintenance therapy
-0,5 -0,4 -0,3 -0,2 -0,1 0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1
HDL-c, MD
Log2
-0,5 -0,4 -0,3 -0,2 -0,1 0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1
HDL-c, MD
Log2
Ma intenance Study MD LL UL P-value I2
Steroids - - - - - -
Anti-TNFα Schulte (2018) [30] -0.04 -0.22 0.14
Miranda-Bautista (2014) [14] 0.04 -0.05 0.15
Pooled 0.02 -0.06 0.11 0.568 0%
Tofacitinib Biemans (2019) [26] 0,20 0.08 0.32
OCTAVE Sustain (2017) [10] 0,17 0.13 0.20
Pooled 0.17 0.13 0.20 <0.001 0%
Induction Study MD LL UL P-value I2
Steroids - - - - - -
Anti-TNFα Schulte (2018) [30] -0.02 -0.14 0.14 - -
Tofacitinib Honap (2020) [25] 0.14 0.03 0.25
OCTAVE phase 2 (2012) [27] 0.14 0.11 0.18
OCTAVE P3 I1 (2017) [10] 0.30 0.27 0.33
OCTAVE P3  I2 (2017) [10] 0.31 0.28 0.33
Pooled 0.24 0.14 0.31 <0.001 95%
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patients have not been described before. In the general population, 
premenopausal women tend to have higher HDL- c levels and lower 
LDL- c and triglyceride levels. Likewise, age and BMI were posi-
tively correlated with total cholesterol levels. Ageing is known to 
be associated with lipid disorders, however greater lipid- modifying 
effect of IBD treatment with increasing age was not reported be-
fore. A direct relationship between increasing BMI and total cho-
lesterol changes was not found. Therefore, it is unlikely that total 
cholesterol changes are partially explained by weight gain, which 
is a known adverse effect of corticosteroids and also described in 
tofacitinib and anti- TNFα agents.12,19 The role of improvement in 
general condition and nutritional state due to mucosal healing has 
not been clarified.
Substantial gaps in our understanding invite for further study. 
The complex interplay between inflammatory cells and lipid me-
tabolism remains to be elucidated. Kinetic studies of lipid metab-
olism would be useful to differentiate between catabolic causes 
(dominant pathways) and anabolic causes (use of anti- inflammatory 
F I G U R E  4   Mean change in LDL- c after induction and maintenance therapy
-0,5 -0,4 -0,3 -0,2 -0,1 0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1
LDL-c, MD
Log2
-0,5 -0,4 -0,3 -0,2 -0,1 0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1
LDL-c, MD
Log2
Induction Study MD 95% LL 95% UL P-value I2
Steroids - - - - - -
Anti-TNFα Schulte (2018) [30] -0.06 -0.16 0.04 - -
Tofacitinib Honap (2020) [25] 0.23 0.13 0.33
OCTAVE phase 2 (2012) [27] 0.09 0.05 0.14
OCTAVE P3 I1 (2017) [10] 0.18 0.15 0.21
OCTAVE P3 I2 (2017) [10] 0.23 0.20 0.27
Pooled 0.18 0.12 0.25 <0.001 90%
Maintenance Study MD 95% LL 95% UL P-value I2
Steroids - - - - - -
Anti-TNFα Schulte (2018) [30] 0.04 -0,07 0.14
Miranda-Bautista (2014) [14] -0.05 -0,14 0.05
Pooled -0.01 -0.10 0.07 0.568 21%
Tofacitinib Biemans (2019) [26] 0.29 0.16 0.42
OCTAVE Sustain (2017) [10] 0.19 0.16 0.24
Pooled 0.22 0.14 0.30 <0.001 45%
F I G U R E  5   Mean change in triglycerides after induction and maintenance therapy.  
Abbreviations: Forest plots visualizing effect sizes of drug classes on lipid profiles, expressed as pooled mean difference on the Log2 scale. LL, lower 
limit; MD, mean difference; UL, upper limit
-0,5 -0,4 -0,3 -0,2 -0,1 0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1
Triglycerides, MD
Log2
-0,5 -0,4 -0,3 -0,2 -0,1 0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1
Triglycerides, MD
Log2
Induction Study MD 95% LL 95% UL P-value I2
Steroids Farkas (2014) [9] 0.28 -0.10 0.66
Pigniczki (2019) [13] -0.01 -0.25 0.24
Pooled 0.10 -0.17 0.37 0.467 36%
Anti -TNFα Schulte (2018) [30] -0.02 -0.23 0.14 - -
Tofacitinib OCTAVE phase 2 (2012) [27] 0.02 -0.06 0.11
OCTAVE P3 I1 (2017) [10] -0.04 -0.09 0.01
OCTAVE P3 I2 (2017) [10] -0.05 -0.06 0.05
Pooled -0.02 -0.05 0.02 0.372 0%
Maintenance Study MD 95% LL 95% UL P-value I2
Steroids Farkas (2014) [9] -0.07 -0.31 0.18 - -
Anti-TNFα Schulte (2018) [30] -0.15 -0.39 0.09
Miranda-Bautista (2014) [14] 0 -0.14 0.15
Balint (2013) [29] 0 -0.45 0.45
Pooled 0.04 -0.16 0.08 0.532 0%
Tofacitinib Biemans (2019) [26] -0.18 -0.43 0.06
OCTAVE Sustain (2017) [10] -0.08 -0.14 -0.01
Pooled -0.08 -0.15 -0.02 0.012 0%
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agents) of drug- induced lipid increases. To further understand the 
link between lipids and cardiovascular risk in IBD, lipidomics and 
proteomics of LDL- c and HDL- c (eg levels, composition and function 
of lipoprotein subfractions not detectable using standard laboratory 
tests) might reveal potential atherogenicity. Especially of interest 
in IBD is the influence of local intestinal inflammation on lipid me-
tabolism and homeostasis. Moreover, clinical studies might address 
the lipid- modulating effect of other drug classes, including immuno-
modulators and newer biologic agents. Proper assessment of inflam-
matory burden (clinical disease activity scores, faecal calprotectin 
and endoscopic findings) might add to current findings. To confirm a 
potential cardiovascular effect of these treatment modalities, trials 
with specific cardiovascular endpoints are needed. The clinical use 
of lipid measurements in IBD requires further development.
The strength of our study is that this is the first comprehensive 
systematic review and meta- analysis assessing the effect of differ-
ent classes of IBD therapy on lipid levels. Moreover, we had access 
to individual patient data of 8 out of 11 studies. Some limitations 
should be taken into consideration. First, the majority of observa-
tional studies lacked a control group (non- exposed IBD patients or 
healthy controls). As a consequence, correction for natural varia-
tions could not be made, illustrated by the modest increase in lipids 
in patients randomised to placebo in the OCTAVE trials.19 Secondly, 
in most studies (9/11) the use of lipid- lowering medication was not 
mentioned. As a result, we cannot eliminate an effect of drug in-
teraction or in- between intervention (eg start of statins) for hyper-
lipidaemia. Miranda- Bautista et al showed that normolipidaemic 
patients were more prone to lipid changes as compared to hyperlip-
idaemic patients.14 Since previous studies showed that the number 
of IBD patients using statins is very low, the missing data on statin 
use have probably not affected our results.42 Thirdly, insufficient 
data were available to draw firm conclusions regarding changes in 
HDL- c, LDL- c and TG levels. Subsequent calculation of atherogenic 
indices (eg total cholesterol/HDL- c or LDL- c/HDL- c ratio) might be 
better predictors of cardiovascular risk.7 Moreover, a type 2 error 
might be introduced for variables only assessed in small cohorts, 
such as the effect IBD subtype on lipid profiles. Lastly, high levels 
of heterogeneity were found between studies. For corticosteroids, a 
possible explanation could be the variety of modes of administration 
as well as different doses used in studies. In the tofacitinib studies, 
both real- life cohorts and pivotal trials were included, which differ 
not only in sample size but also in clinical characteristics, for exam-
ple only 30% of patients qualify for enrolment in these studies.43 
Heterogeneity was lowest among anti- TNFα studies. Nevertheless, 












Corticosteroids Total cholesterol Induction 4.27 1.25 0.31 2.39
Maintenance 3.56 1.29 0.40 2.38
HDL- c Induction — — — — 
Maintenance — — — — 
LDL- c Induction — — — — 
Maintenance — — — — 
Triglycerides Induction 1.16 0.08 −0.13 0.34
Maintenance — — — — 
Anti- TNFα agents Total cholesterol Induction 4.65 −0.12 −0.41 0.20
Maintenance 4.64 0.08 −0.14 0.32
HDL- c Induction — — — — 
Maintenance 1.30 0.02 −0.05 0.10
LDL- c Induction — — — — 
Maintenance 2.57 −0.02 −0.17 0.13
Triglycerides Induction — — — — 
Maintenance 0.91 −0.02 −0.09 0.05
Tofacitinib Total cholesterol Induction 4.62 0.65 0.47 0.84
Maintenance 4.60 0.55 0.43 0.68
HDL- c Induction 1.42 0.24 0.15 0.34
Maintenance 1.49 0.18 0.15 0.22
LDL- c Induction 2.56 0.35 0.21 0.48
Maintenance 2.60 0.42 0.26 0.60
Triglycerides Induction 1.14 −0.01 −0.01 −0.04
Maintenance 1.13 −0.06 −0.11 −0.01
Abbreviations: LL, lower limit; UL, upper limit.
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selection bias might be introduced since several authors not taking 
part in our meta- analysis support the hypothesis of a lipid increas-
ing effect of anti- TNFα agents in IBD.12,44,45 In line with this, lack 
of data from other registered drug therapies such as immunomod-
ulators (eg thiopurines and methotrexate) and modern biologics (eg 
ustekinumab and vedolizumab) might as well be the consequence of 
reporting bias rather than unavailability of data.
Currently, it is unknown if dyslipidaemia associated with IBD 
treatment plays a role in cardiovascular risk in IBD. Whether a 
drug- induced increase in lipid levels is clinically important, needs 
to be determined on individual patient level and depends on total 
cardiovascular risk, taking into consideration not only lipid levels 
but also other risk factors, such as age, sex, smoking habit and 
blood pressure. Evidence from genetic, epidemiological and clinical 
TA B L E  3   Mean changes in total cholesterol values in relation to IBD treatment
Baseline Follow- up Change
P for comparison 
with tofacitinib
Model 1— Unadjusted effects
Corticosteroids 3.95 4.84 0.89 <0.001
Anti- TNFα agents 4.61 4.49 −0.12 <0.001
Tofacitinib 4.69 5.25 0.55
Model 2— Effects adjusted for sex, age, BMI, CRP, IBD subtype, disease duration, disease extent and concomitant corticosteroid use at baseline
Corticosteroidsa  4.28 5.25 0.96 <0.001
Anti- TNFα agentsa  4.95 4.75 −0.20 <0.001
Tofacitiniba  4.92 5.50 0.58
Baseline Follow- up Change
P for 
interaction
Models 3— Effects of tofacitinib treatment in clinically relevant strata
Sex
Man 4.79 5.32 0.54 0.298
Woman 4.61 5.18 0.56
Age, years
18 4.33 4.72 0.39 0.001
41.3 4.68 5.23 0.55
65 5.06 5.80 0.74
CRP, mg/L
0.3 4.70 5.29 0.59 0.079
3.4 4.68 5.25 0.57
15 4.60 5.13 0.53
BMI, kg/m2
18 4.61 5.11 0.50 0.149
24.3 4.74 5.29 0.56
30 4.85 5.46 0.61
Disease duration, years
1 4.51 5.04 0.53 0.766
9 4.69 5.25 0.56
17 4.88 5.46 0.59
Disease extent
Proctitis 4.89 5.36 0.46 0.061
Left- sided 4.87 5.40 0.54 0.307
Pancolitis 4.61 5.25 0.64 <0.001
Concomitant corticosteroid use at 
baseline
No 4.52 5.08 0.55 0.489
Yes 4.89 5.51 0.63
aMean for patients with “average” sex, age, BMI, CRP, disease duration, disease extent and concomitant steroid use at baseline.
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studies suggest that each mmol/L reduction in LDL- c is associated 
with up to 52% reduction in cardiovascular risk.46 Effects depend 
on the duration of exposure to LDL- c, implicating that long- term 
exposure to even marginal increases in LDL- c can eventually lead 
to substantial cardiovascular risk increase. From a clinical point 
of view, the net effect of improving inflammatory burden but in-
creasing cholesterol levels on cardiovascular risk remains undeter-
mined. Disease remission, biologic therapy and intestinal surgery 
have been associated with reduced incidence of cardiovascular 
events.47,48 However, the majority of patients continue to expe-
rience disease flares, persistent disease activity and short- term 
corticosteroid exposure during their disease course, all associated 
with an increased risk of myocardial infarction, stroke and heart 
failure.49,50 It is as yet uncertain if in IBD patients cholesterol is 
an independent risk factor of cardiovascular disease due to fluc-
tuating patterns of inflammation. Nevertheless, given the elevated 
cardiovascular risk in IBD patients, assessing and treating cardio-
vascular risk factors regardless of inflammation is essential for 
cardiovascular risk prevention. Previous studies suggest the use 
of other methods of risk assessment, such as evaluation of carotid 
intima- media thickness by ultrasonography.5 The development of 
IBD- specific cardiovascular risk assessment tools might help to 
identify patients who will benefit from intervention.
In conclusion, this systematic review and meta- analysis provide 
evidence of an association between drug therapy and lipid changes 
in patients with IBD. Our results support routine evaluation of lipid 
profiles in patients with active disease initiating corticosteroids and 
JAK- STAT inhibitors in daily practice.
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